Grand Pharmaceutical Group Limited Stock price

Equities

512

BMG210A71016

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
4.11 HKD -2.38% Intraday chart for Grand Pharmaceutical Group Limited +1.23% +0.49%
Sales 2023 10.53B 1.35B Sales 2024 * 12.06B 1.54B Capitalization 14.39B 1.84B
Net income 2023 1.88B 240M Net income 2024 * 2.44B 312M EV / Sales 2023 1.37 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.19 x
P/E ratio 2023
7.63 x
P/E ratio 2024 *
6.1 x
Employees -
Yield 2023 *
2.61%
Yield 2024 *
3.09%
Free-Float 28.4%
More Fundamentals * Assessed data
Dynamic Chart
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug MT
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication MT
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial MT
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China MT
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million MT
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan MT
More news
1 day-2.38%
1 week+1.23%
Current month+14.48%
1 month+12.30%
3 months+0.98%
6 months-1.67%
Current year+0.49%
More quotes
1 week
3.91
Extreme 3.91
4.30
1 month
3.35
Extreme 3.35
4.30
Current year
3.17
Extreme 3.17
4.30
1 year
3.17
Extreme 3.17
5.40
3 years
3.17
Extreme 3.17
8.45
5 years
3.17
Extreme 3.17
8.99
10 years
1.27
Extreme 1.27
8.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 34 19-03-31
Corporate Secretary 56 11-08-31
Members of the board TitleAgeSince
Director/Board Member 61 05-03-20
Director/Board Member 60 18-12-30
Director/Board Member 64 11-05-11
More insiders
Date Price Change Volume
24-03-28 4.11 -2.38% 2 625 000
24-03-27 4.21 +2.18% 6,327,500
24-03-26 4.12 +4.30% 7,556,000
24-03-25 3.95 -2.47% 3,830,500
24-03-22 4.05 -0.25% 5,498,000

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.21
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Grand Pharmaceutical Group Limited - Hong Kong S.E.